Peptides Similar to Petrelintide
Compare Petrelintide with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •Cagrilintide: Very high - Both are long-acting amylin analogs for once-weekly obesity treatment
- •Pramlintide: High - Both are amylin analogs, but pramlintide is short-acting
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Petrelintide (current) | - | - |
| Cagrilintide | Very high - Both are long-acting amylin analogs for once-weekly obesity treatment | Cagrilintide is developed by Novo Nordisk and is more advanced in combination with semaglutide (CagriSema). Petrelintide is partnered with Roche. |
| Pramlintide | High - Both are amylin analogs, but pramlintide is short-acting | Pramlintide requires 3 daily injections and is approved for diabetes (not obesity). Petrelintide is once-weekly for obesity. |
| Semaglutide | Low-moderate - Both target weight loss but via completely different receptors | Semaglutide targets GLP-1 receptors. Petrelintide targets amylin receptors. Complementary mechanisms support combination use. |
CagrilintideVery high - Both are long-acting amylin analogs for once-weekly obesity treatment
Differences
Cagrilintide is developed by Novo Nordisk and is more advanced in combination with semaglutide (CagriSema). Petrelintide is partnered with Roche.
Advantages
More advanced development (Phase 3 CagriSema), larger dataset, Novo Nordisk resources
Disadvantages
CagriSema is fixed combination; petrelintide may offer flexible combination approach
PramlintideHigh - Both are amylin analogs, but pramlintide is short-acting
Differences
Pramlintide requires 3 daily injections and is approved for diabetes (not obesity). Petrelintide is once-weekly for obesity.
Advantages
FDA-approved, established safety profile, decades of clinical experience
Disadvantages
Requires 3 daily injections, approved only for diabetes with insulin, black box warning for hypoglycemia
SemaglutideLow-moderate - Both target weight loss but via completely different receptors
Differences
Semaglutide targets GLP-1 receptors. Petrelintide targets amylin receptors. Complementary mechanisms support combination use.
Advantages
FDA-approved, proven 14.9% weight loss, CV benefit, extensive data
Disadvantages
Different mechanism; combination with amylin may enhance efficacy beyond GLP-1 alone
Agents Related to Petrelintide#
Petrelintide belongs to the amylin analog class, competing most directly with Novo Nordisk's cagrilintide. Both aim to leverage amylin's satiety mechanism for obesity treatment, but differ in their partnership and combination strategies.
| Feature | Petrelintide | Cagrilintide | Pramlintide | Semaglutide |
|---|---|---|---|---|
| Type | Long-acting amylin | Long-acting amylin | Short-acting amylin | GLP-1 agonist |
| Route | SC weekly | SC weekly | SC 3x daily | SC weekly / oral |
| Weight loss | 8.6% (Phase 1b) | ~10.8% (mono) | ~2-3% | 14.9% |
| Combination | ZUPREME-2 | CagriSema (Phase 3) | With insulin | N/A |
| Partner | Roche ($5.3B) | Novo Nordisk | Amylin/AZ | Novo Nordisk |
| Regulatory | Phase 1b/2b | Phase 2/3 | Approved (T2D) | Approved |
Comparison Context#
Petrelintide belongs to the Metabolic category of research peptides. Comparing Petrelintide with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.
Detailed Comparisons#
The following peptides and compounds are most closely related to Petrelintide in mechanism, indication, or therapeutic category:
Petrelintide vs Cagrilintide#
Similarity: Very high - Both are long-acting amylin analogs for once-weekly obesity treatment
Key Differences: Cagrilintide is developed by Novo Nordisk and is more advanced in combination with semaglutide (CagriSema). Petrelintide is partnered with Roche.
Advantages of Cagrilintide: More advanced development (Phase 3 CagriSema), larger dataset, Novo Nordisk resources
Disadvantages of Cagrilintide: CagriSema is fixed combination; petrelintide may offer flexible combination approach
Researchers choosing between Petrelintide and Cagrilintide should consider the development stage, available evidence, and specific research objectives when making their selection.
Petrelintide vs Pramlintide#
Similarity: High - Both are amylin analogs, but pramlintide is short-acting
Key Differences: Pramlintide requires 3 daily injections and is approved for diabetes (not obesity). Petrelintide is once-weekly for obesity.
Advantages of Pramlintide: FDA-approved, established safety profile, decades of clinical experience
Disadvantages of Pramlintide: Requires 3 daily injections, approved only for diabetes with insulin, black box warning for hypoglycemia
Researchers choosing between Petrelintide and Pramlintide should consider the development stage, available evidence, and specific research objectives when making their selection.
Petrelintide vs Semaglutide#
Similarity: Low-moderate - Both target weight loss but via completely different receptors
Key Differences: Semaglutide targets GLP-1 receptors. Petrelintide targets amylin receptors. Complementary mechanisms support combination use.
Advantages of Semaglutide: FDA-approved, proven 14.9% weight loss, CV benefit, extensive data
Disadvantages of Semaglutide: Different mechanism; combination with amylin may enhance efficacy beyond GLP-1 alone
Researchers choosing between Petrelintide and Semaglutide should consider the development stage, available evidence, and specific research objectives when making their selection.
Related Reading#
Frequently Asked Questions About Petrelintide
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer